Skip to main content

Phanes Therapeutics Raises $40 Million for mAb and Bi-specific Portfolio

Phanes Therapeutics, a San Diego-Shanghai immunoncology company, completed a $40 million Series B financing. The company is developing a pipeline of seven mAb and bi-specific pre-clinical candidates that it discovered using its two technology platforms. The B round was led by Sequoia Capital China. Phanes said it would use the proceeds to advance several pre-clinical programs into the clinic, expand its research and clinical teams, and advance new research projects. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.